GlassScriptPhysician profile
Adam T Gomoll
NPI 1598730715
$6,469.05
in general payments reported to CMS, 2019-2025
25 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $1,177 · 2023: $1,089 · 2024: $1,692 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,724 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,724.39 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,004.56 | 2021-2025 | Tremfya, Xarelto |
| Abbvie INC. | $626.50 | 2021-2025 | |
| Dermavant Sciences, INC. | $617.31 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $526.35 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $474.14 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $454.29 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $395.10 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $379.52 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $302.28 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $286.72 | 2021-2025 | Bimzelx, Cimzia |
| Organon LLC | $243.45 | 2024-2025 | Vtama |
| Galderma Laboratories, L.P. | $195.65 | 2022-2025 | Nemluvio, Twyneo, Aklief |
| E.R. Squibb & Sons, L.L.C. | $182.87 | 2022-2025 | Sotyktu |
| Incyte Corporation | $156.20 | 2022-2025 | Opzelura |
| Pfizer INC. | $151.24 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $120.77 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.73 | 2023-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $65.53 | 2022-2025 | |
| Leo Pharma INC. | $64.76 | 2021-2025 | Adbry |
| Almirall LLC | $47.34 | 2022-2023 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.99 | 2024 | Cabtreo |
| Kerecis Limited | $22.24 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Genentech USA, INC. | $16.11 | 2023 | Xolair |
| Strata Skin Sciences, INC. | $14.06 | 2025 | Xtrac |
| Biofrontera INC. | $10.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Gomoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.